Treatment of adverse radiation effects with *Boswellia serrata* after failure of pentoxifylline and vitamin E: illustrative cases

Ronald E. Warnick, MD

Department of Neurosurgery, Mayfield Clinic, Cincinnati, Ohio; and Gamma Knife Center, Jewish Hospital, Cincinnati, Ohio

**BACKGROUND** Adverse radiation effects (AREs) can occur after stereotactic radiosurgery (SRS), and symptomatic cases are often treated with corticosteroids, pentoxifylline, and vitamin E. The supplement 5-Loxin (*Boswellia serrata*) is an extract of Indian frankincense that inhibits vascular endothelial growth factor expression and has been shown to reduce perilesional edema in brain tumor patients undergoing fractionated radiation.

**OBSERVATIONS** Three patients underwent SRS for meningioma or metastasis and developed symptomatic AREs at 4 to 8 months. They were initially treated with corticosteroids, pentoxifylline, and vitamin E with transient improvement followed by recurrent neurological symptoms and imaging findings as steroids were tapered off. All patients were rescued by the administration of 5-Loxin with resolution of neurological symptoms and imaging changes, discontinuation of steroids, and no medication side effects.

**LESSONS** The author’s early experience with 5-Loxin has been encouraging, and this supplement has become the author’s first-line treatment for acute radiation effects after SRS. The author reserves bevacizumab for significant mass effect or failure of oral therapy. 5-Loxin has many advantages including low cost, ease of use, and patient tolerability. More experience is needed to confirm the role of 5-Loxin in the upfront treatment of AREs.

https://thejns.org/doi/abs/10.3171/CASE22488

**KEYWORDS** stereotactic radiosurgery; adverse radiation effects; meningioma; brain metastasis; *Boswellia serrata*; pentoxifylline
volume was contoured on the T1-weighted contrast sequence and perilesional edema was measured on the FLAIR sequence. A graph was generated for each patient correlating neurological symptoms, steroid dose, and volumetric data.

Illustrative Cases

Case 1
A 33-year-old male with Proteus syndrome presented with multiple meningiomas. Serial MRI scans showed gradual enlargement of an anterior frontal falci ne meningioma (1.8 cm maximal diameter). The patient underwent Novalis (Brainlab) single-fraction, frameless stereotactic radiosurgery (13 Gy prescription dose). Five months after SRS, the patient returned with frontal headaches, and repeat MRI showed a rim of parenchymal enhancement and significant bifrontal edema (Fig. 1). He was started on dexamethasone 4 mg four times a day, pentoxifylline 400 mg three times a day, and vitamin E 400 IU twice a day. His headaches and ARE imaging findings improved but then recurred after steroids were tapered off. Trimodal therapy was restarted with a similar result (i.e., recurrence after steroid taper). Pentoxifylline and vitamin E were considered to have failed since the patient remained dependent on steroids and his quality of life was limited by significant weight gain and fatigue.

We discussed the option of resecting the falcine meningioma or initiating bevacizumab infusions but ultimately started 5-Loxin 150 mg twice a day. The patient was successfully tapered off steroids 3 months later without return of headaches. Follow-up MRI scans showed complete resolution of parenchymal enhancement and perilesional edema and 61% reduction in meningioma volume. The patient continued 5-Loxin for 28 months without adverse effects.

Case 2
A 59-year-old female presented with a gradually enlarging olfactory groove meningioma (2.5 cm maximal diameter). The patient underwent Novalis 5-fraction, frameless stereotactic radiosurgery (25 Gy total prescription dose). Eight months after SRS, the patient complained of frontal headaches and mild confusion. MRI showed irregular parenchymal enhancement and increased bifrontal edema with effacement of the right lateral ventricle (Fig. 2). She was started on dexamethasone 4 mg four times a day, pentoxifylline 400 mg three times a day, and vitamin E 400 IU twice a day. She initially responded to this therapy but her headaches and ARE imaging findings recrudesced as steroids were tapered off. Trimodal therapy was reinstituted with a similar beneficial response, but subsequent MRI showed increased perilesional edema when steroids...
were again discontinued. We judged pentoxifylline and vitamin E to have failed, as the patient remained steroid-dependent despite 12 months of treatment. We discussed surgery to resect the olfactory meningioma, hyperbaric oxygen therapy (HBO), or bevacizumab. After considering all options, the patient was started on 5-Loxin 150 mg twice a day without steroids. Follow-up MRI showed an 87% reduction in perilesional edema, resolution of mass effect, and 73% decrease in tumor volume. The patient continued 5-Loxin for a total of 17 months without side effects.

Case 3
A 74-year-old male with melanoma metastatic to the lung presented with right-sided hyperreflexia. MRI revealed a 1.5-cm left motor area metastasis, and the patient underwent Novalis single-fraction, frameless SRS (18 Gy prescription dose). MRI 4 months after SRS showed slight tumor enlargement with hazy enhancing borders and significantly increased perilesional edema (Fig. 3). The patient was started on pentoxifylline 400 mg three times a day and vitamin E 400 IU twice a day. At 9 months, he developed progressive right-hand numbness and began dexamethasone. MRI scans showed gradual improvement in AREs until 15 months after SRS when the patient developed right hand weakness and repeated MRI demonstrated increasing perilesional edema. Pentoxifylline was deemed to be a failure, and we discussed the options of HBO or bevacizumab (surgery was contraindicated based on location). The patient elected to start 5-Loxin 150 mg twice a day. He gradually returned to his neurological baseline and follow-up scans showed complete resolution of perilesional edema and minimal residual enhancement. The patient continued 5-Loxin for 24 months without side effects.

Discussion
Observations
In this report, three patients who underwent SRS for meningioma or brain metastasis complicated by symptomatic AREs at 4 to 8 months are described. They were initially treated with steroids, pentoxifylline, and vitamin E with transient improvement followed by recurrent neurological symptoms and imaging findings as steroids were tapered off. All patients were rescued by the administration of 5-Loxin (Boswellia serrata) with resolution of symptoms and imaging changes, discontinuation of steroids, and no medication side effects.
The incidence of ARE after radiosurgery is increasing due to several factors: (1) greater use of SRS for brain metastasis (nearly replacing whole brain radiation), (2) repeated courses of SRS in patients who are living longer with their primary cancer, and (3) negative synergy between SRS and immunotherapy. The treatment options for ARE have evolved over the last 2 decades. Half of these patients have neurological symptoms requiring initiation of corticosteroids. The duration of steroid use varies but many patients experience significant toxicity including immunosuppression, weight gain, hyperglycemia, hypertension, and osteoporosis. The oral combination of pentoxifylline and vitamin E has shown benefit in the treatment of ARE in extracranial soft tissues and in the setting of radiation necrosis after cranial SRS.2 Nonpharmacological interventions include surgery, laser-induced thermal therapy, and HBO.4 Several lines of evidence point to the role of VEGF in the formation of perilesional edema after SRS. Kan et al.5 demonstrated that VEGF expression in meningiomas was correlated with the development of peritumoral edema after radiosurgery. A subsequent study measured plasma VEGF levels in meningioma patients after SRS and noted elevated plasma VEGF levels in patients who developed perilesional edema.6 These and other studies support the causal role of VEGF secretion in the development of ARE through neovascularization, increased vascular permeability, and brain edema. Two randomized controlled trials and multiple retrospective studies have demonstrated the efficacy of bevacizumab for symptomatic brain radiation necrosis.7,8 Overall, 91% of patients showed clinical improvement and 85% had a radiographic response. Adverse events occurred in 14% to 55% of patients and were mainly grade 1 or 2 (fatigue, hypertension, proteinuria) and less commonly grade 2 (cerebral ischemia, deep-vein thrombosis, pulmonary embolus). However, bevacizumab (Avastin) requires an implanted venous access device and is expensive ($5,000–$7,000 per injection). Therefore, there is a compelling need for an inexpensive, oral agent for the treatment of ARE in patients with brain tumors who have undergone SRS.

Boswellia serrata is an extract of Indian frankincense and contains at least six different boswellic acids including the main bioactive component AKBA. AKBA is a potent inhibitor of HIF-1α, which results in downstream inhibition of VEGF expression.3 In a murine model of oxygen-induced retinopathy, AKBA inhibited VEGF expression and reduced pathologic neovascularization (endothelial cell proliferation, migration, and tube formation).9 Thus, AKBA was viewed as a potential agent for the prevention of the neovascularization and increased vascular permeability associated with radiation injury.

Kirste et al.10 performed a randomized, placebo-controlled, double-blind study of Boswellia serrata in malignant brain tumor patients undergoing radiosurgery.
fractionated radiation. Forty-four patients with glioblastoma or brain metastases were randomly assigned to radiotherapy plus either *Boswellia serrata* 4,200 mg/d or placebo. The primary endpoint was peritumoral edema on T2-weighted MRI scans. A reduction in brain edema of ≥75% was noted in 60% of patients receiving *Boswellia serrata* compared to 25% of patients receiving the placebo. Adverse events attributed to the study drug were limited to 6 of 20 patients who developed grade 1 to 2 diarrhea. A randomized placebo-controlled study of 5-Loxin for osteoarthritis of the knee established a favorable safety profile. Adverse events were limited to gastrointestinal symptoms including diarrhea (8%), nausea (10%), and abdominal pain (4%).

5-Loxin is a patented, standardized extract of *Boswellia serrata* that provides 30% AKBA by weight. 5-Loxin is readily available in the United States (Vitagost.com) and is inexpensive (approximately $20 per month). *Boswellia serrata* is lipophilic, and therefore, food intake has a significant effect on its absorption. Sterk et al. measured plasma levels of AKBA in healthy volunteers who received *Boswellia serrata* while fasting or after ingestion of a high-fat meal. The mean total area under the plasma concentration-time curve was 387% higher in patients with concomitant fatty food intake. The adverse events were limited to gastrointestinal symptoms including diarrhea (8%), nausea (10%), and abdominal pain (4%).

These emerging studies prompted us to prescribe 5-Loxin to three patients with adverse radiation effects in whom standard oral therapy with pentoxifylline and vitamin E had failed. All patients were successfully weaned off steroids and MRI scans confirmed resolution of ARE imaging changes. Radiation injury may spontaneously regress, and the impact of a pharmacological intervention may be difficult to determine. Cases 1 and 2 had each failed two courses of trimodal therapy and the patients remained steroid-dependent. Therefore, it is unlikely that the clinical and radiographic responses after initiation of 5-Loxin were spontaneous and coincidental. For case 3, we were encouraged by our initial experience and prescribed 5-Loxin after the first failure of pentoxifylline and vitamin E with similar beneficial results. None of our patients experienced any side effects while taking 5-Loxin, and overall, less than 1% of patients taking 5-Loxin will experience transient gastrointestinal side effects. The duration of 5-Loxin in our report (17–28 months) was largely a patient choice to prevent subsequent recurrence of ARE.

We now use 5-Loxin for patients who have MRI findings of ARE without mass effect. We reserve surgery and bevacizumab for patients who are either highly symptomatic or demonstrate mass effect. We hope to gain sufficient experience with 5-Loxin in the upfront treatment of ARE for a future report. We also envision the potential of 5-Loxin as a prophylactic agent to prevent ARE after SRS especially in patients undergoing SRS followed by immunotherapy.

Lessons

Our early experience with the supplement 5-Loxin has been encouraging and it has become our first-line treatment for acute radiation effects after SRS because of low cost, ease of use, and patient tolerability. We reserve bevacizumab for significant mass effect or failure of oral therapy. More experience is needed to confirm the role of 5-Loxin in the upfront treatment of ARE including timing and optimal dose.

Acknowledgments

We would like to thank Martha Headworth and Tonya Hines for illustration of the case infographics and Laura Mancini for medical editing.

References


Disclosures

The author reports no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

Correspondence

Ronald E. Warnick: Mayfield Clinic, Cincinnati, OH. editor@mayfieldclinic.com.